Inflammatory and immunologic analysis of bronchoalveolar lavage from patients with post-COVID-19 lung disease 🚨New BAL study finds 3 distinct inflammatory phenotypes in post-COVID lung disease (lymphocytic, neutrophilic, normal), but no clear match to CT patterns or outcomes. Persistent viral protein may keep the fire burning! ➡️Clinical bronchoalveolar lavage (BAL) fluid from 37 patients with suspected post-COVID-19 lung disease (5 acute <28 days; 32 post-acute, median 178 days post-PCR, range up to ~2 years) were analysed in this interesting USA study( 2020-2022), ➡️BALs were collected from Oct 2020 through early May 2022, and clinical follow-up extended to early 2026 (or death/last chart note), ➡️Samples were assessed for cell differentials, SARSCoV2 spike protein (ELISA), and local antibody responses, then correlated with chest CT patterns and clinical outcomes, ➡️Three inflammatory phenotypes emerged: - Lymphocytic-predominant (lymphocytes ≥15% and >neutrophils; ~32%), - Neutrophilic-predominant (neutrophils ≥10% and >lymphocytes; ~35%), and - Normal cellular differential (~19%), ➡️Spike protein was detected in acellular BAL in ~49% of subjects (higher than controls), persisting up to 627 days post-infection, ➡️Local antibody responses were common: total anti-SARSCoV2 antibodies in 61% of tested samples and neutralizing activity in 30%, ➡️No clear association was found between BAL inflammatory pattern, CT findings (ground-glass, interstitial, mixed, or other), or long-term outcomes (alive/no oxygen vs. death/transplant/oxygen), ➡️The authors conclude that post-COVID lung disease is heterogeneous, with distinct inflammatory milieus potentially driven in part by persistent viral protein. ‼️So, post-COVID lung disease is not one disease but a spectrum of lingering lung inflammation, sometimes with residual spike protein detectable years later, that defies simple links to imaging or outcomes and complicates both diagnosis and research. ‼️For people with ongoing breathlessness, fatigue, or other post-COVID symptoms, this underscores that lung inflammation can persist long after the acute infection clears and that residual viral proteins may contribute. It supports the reality of heterogeneous LongC0VID lung issues, the value of targeted investigations (like BAL in selected cases), and the need AGAIN for personalized approaches rather than one-size-fits-all assumptions. It also highlights why broad clinical trials based only on symptoms demonstrate difficulties to interpret! #LongC0VID #PostCOVID #AvoidSars2 #AvoidReinfections frontiersin.org/journals/mic…